SOUTHLAKE, Texas – September 14, 2022 – OncoNano Medicine, Inc. today announced a presentation of…
Read More
– Oncology Development Veteran to Lead the Advancement of OncoNano’s Portfolio SOUTHLAKE, Texas – June…
SOUTHLAKE, Texas – May 10, 2022 – OncoNano Medicine, Inc. today announced the appointment of…
– ONM-501 is a dual-activating polyvalent STING agonist for immuno-oncology applications formulated with OMNI™, the…
SOUTHLAKE, Texas – April 12, 2022 – OncoNano Medicine, Inc. today announced positive results from…
March 10, 2022 SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced two poster presentations at the…
– Former Assistant Secretary of Health and Admiral in the U.S. Public Health Service to…
-Will convert previous grant awards to an equity investment in OncoNano’s Series B -Additional capital…
Update on pH-sensitive fluorescent nanoprobe from late-breaking oral presentation at The World Molecular Imaging Congress…
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology…